Overdose Risk with Selective Serotonin Reuptake Inhibitors: The Authors' Reply

Edwards, J.G.; Anderson, I.
December 1999
Drugs;Dec1999, Vol. 58 Issue 6, p1206
Academic Journal
Replies to a commentary on an article which focused on the overdose risk of selective serotonin reuptake inhibitors (SSRI) in patients with depression. Claim on the presentation of a systematic review and meta-analysis of the efficacy and tolerability of comparative studies on SSRI; Explanation to conclusions given on citalopram.


Related Articles

  • Overdose Risk with Selective Serotonin Reuptake Inhibitors. Muldoon, C. // Drugs;Dec1999, Vol. 58 Issue 6, p1205 

    Comments on an article which focused on specific statements made about overdoses with citalopram, a selective serotonin reuptake inhibitor. Precaution given by treatment guidelines from standard works in dealing with depressed patients; Analysis of papers that contain data relating to overdose...

  • Dense Cranial Electroacupuncture Stimulation for Major Depressive Disorder--A Single-Blind, Randomized, Controlled Study. Zhang-Jin Zhang; Roger Ng; Sui Cheung Man; Tsui Yin Jade Li; Wendy Wong; Qing-Rong Tan; Hei Kiu Wong; Ka-Fai Chung; Man-Tak Wong; Wai-Kiu Alfert Tsang; Ka-chee Yip; Eric Ziea; Vivian Taam Wong // PLoS ONE;Jan2012, Vol. 7 Issue 1, p1 

    Background: Previous studies suggest that electroacupuncture possesses therapeutic benefits for depressive disorders. The purpose of this study was to determine whether dense cranial electroacupuncture stimulation (DCEAS) could enhance the antidepressant efficacy in the early phase of selective...

  • Tryptophan depletion in SSRI-recovered depressed outpatients. Spillmann, Maya K.; Van der Does, A.J. Willem; Rankin, Meridith A.; Vuolo, Rachel D.; Alpert, Jonathan E.; Nierenberg, Andrew A.; Rosenbaum, Jerrold F.; Hayden, Douglas; Schoenfeld, David; Fava, Maurizio // Psychopharmacology;2001, Vol. 155 Issue 2, p123 

    Abstract Rationale: Recently, a number of studies have challenged the finding that acute tryptophan depletion (TD) increases depressive symptoms in medicated, formerly depressed patients. The present study examined the effects of acute nutritional TD on remitted depressed patients currently...

  • New psych agents under study offer multiple benefits. Aelxander, Walter // Drug Topics;6/21/2004, Vol. 148 Issue 12, p34 

    This article reports on the multiple benefits provided by duloxetine. The agent is a potent norepinephrine /serotonin reuptake inhibitor. Duloxetine is capable of alleviating both mood and painful physical symptoms of major depressive disorder. Significant improvement in mood and painful...

  • Coste-efectividad de venlafaxina en el tratamiento de la depresión y de la ansiedad. Revisión bibliográfica. Baldomero, E. Baca; Rubio-Terrés, C. // Actas Espanolas de Psiquiatria;may2006, Vol. 34 Issue 3, p193 

    Objective. To compare the efficiency of the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) with venlafaxine in comparison with tricyclic antidepressants (TCA) and selective serotonin reuptake inhibitors (SSRI). Methods. A bibliographic systematic review of...

  • Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder. Dubicka, Bernadka; Ramchandani, Paul // Evidence Based Medicine;Apr2005, Vol. 10 Issue 2, p46 

    The article cites a research study, which revealed that fluoxetine plus cognitive behavioral therapy (CBT) was most effective for adolescents with major depressive disorder. The researchers concluded that in adolescents with major depressive disorder, fluoxetine plus cognitive behavioral therapy...

  • Prescribing for depression. Newson, Louise // GP: General Practitioner;4/21/2006, p50 

    The article focuses on the treatment of depression. Depression is considered to be a common and debilitating condition. According to meta-analysis, Selective Serotonin Reuptake Inhibitors (SSRIs) and low-dose tricyclic antidepressants are effective in treating depression in primary care. This is...

  • Treating Depression: What You Should Know.  // American Family Physician;3/15/2008, Vol. 77 Issue 6, p795 

    The article presents questions and answers related to mental depression including the treatments for the disorder, side effects of selective serotonin reuptake inhibitors (SSRI), and information resources.

  • Vortioxetine approved for major depressive disorder.  // WHO Drug Information;2013, Vol. 27 Issue 4, p359 

    The article discusses the U.S. Food and Drug Administration's (FDA) approval of vortioxetine for the treatment of adults with major depressive disorder.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics